PCM
ACER

Prelude Capital Management’s Acer Therapeutics Inc ACER Stock Holding History

Prelude Capital Management’s Portfolio ACER Stock Details ACER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-821
Closed -$3K – 2489
2020
Q2 		$3K Buy
+821
New +$2.32K ﹤0.01% 1804

Other funds holding ACER

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Prelude Capital Management's ACER Position: Q3 2020 in Review

Prelude Capital Management sold out of Acer Therapeutics Inc (ACER) in Q3 2020, closing a stake of 821 shares — an estimated $3K sold.

Prelude Capital Management first reported a position in ACER in Q2 2020 and held it in 1 quarter. The position peaked at $3K in Q2 2020. 27 funds tracked by Wall St. Rank hold ACER as of Q3 2020.

  • Prelude Capital Management reported no remaining Acer Therapeutics Inc position as of Q3 2020 after selling out during the quarter.
  • Prelude Capital Management sold 821 Acer Therapeutics Inc shares in Q3 2020, an estimated $3K.
  • Prelude Capital Management first reported a position in Acer Therapeutics Inc in Q2 2020 and held it in 1 quarter.
  • Prelude Capital Management's Acer Therapeutics Inc position peaked at $3K in Q2 2020.
  • 27 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q3 2020.

Based on Prelude Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.